Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Growth in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 372,384 shares, a growth of 281.1% from the December 31st total of 97,715 shares. Based on an average daily trading volume, of 2,377 shares, the short-interest ratio is presently 156.7 days. Based on an average daily trading volume, of 2,377 shares, the short-interest ratio is presently 156.7 days.

Innovent Biologics Stock Performance

IVBXF stock traded up $0.43 during midday trading on Wednesday, reaching $10.40. The stock had a trading volume of 2,485 shares, compared to its average volume of 1,577. Innovent Biologics has a 52-week low of $4.25 and a 52-week high of $15.12. The firm has a fifty day simple moving average of $11.00 and a two-hundred day simple moving average of $11.65.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).